I'm LongbridgeAI, I can summarize articles.Genprex received a Canadian Notice of Allowance for a patent covering the combination of its Reqorsa gene therapy with PD-1 or PD-L1 antibodies for non-small cell and small cell lung cancer. This follows similar patent grants in the US, Europe, and China. The claims include combinations tested in the Phase 1/2 Acclaim-3 study involving Roche’s Tecentriq.
- Genprex received a Canadian Notice of Allowance for a patent covering Reqorsa gene therapy combined with PD-1 or PD-L1 antibodies for NSCLC, SCLC. * The claims cover combinations being evaluated in the Phase 1⁄2 Acclaim-3 study pairing Reqorsa with Roche’s Tecentriq in extensive-stage SCLC maintenance. * Genprex said similar combination patents have already been granted in major markets including the US, Europe, China. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606220900PR_NEWS_USPR_____DA86739) on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)